Novel Biomarkers of Pulmonary Hypertension

• Published in: Kardiologiia Vol. 59; no. 7; p. 84
• Main Authors: Gaynitdinova, V V, Avdeev, S N
• Format: Journal Article
• Language: English; Russian
• Published: Russia (Federation) 19-07-2019
• Subjects: Biomarkers; Cardiac Catheterization; Echocardiography; Heart Ventricles; Humans; Hypertension, Pulmonary; Pulmonary Artery; Ventricular Dysfunction, Right
• ISSN: 0022-9040
• DOI: 10.18087/cardio.2019.7.10259

Pulmonary hypertension (PH) is a clinical syndrome characterized by a progressive increase in pulmonary vascular resistance (PVR), which leads to remodeling of the right ventricle (RV), right heart failure and premature death of patients. Early diagnosis and monitoring of disease progression are crucial for making decisions about the necessary therapy. The gold standard for the diagnosis of pulmonary hypertension is the right heart catheterization. The estimation of systolic pressure in pulmonary artery by means of transthoracic echocardiography is also used for monitoring the course of the disease. At present, there is still a need for non-invasive biomarkers that reflect pathological changes in pulmonary arterial vessels and allow diagnosing of PH. Our review outlines the new data about some biomarkers potentially useful for diagnosis and prognostication of PH. These biomarkers (mid-regional pro-adrenomedullin, carboxyterminal pro-endothelin-1, copeptin, asymmetric dimethylarginine, growth differentiation factor 15, and others) are classified based on their relationship to endothelial cell dysfunction, inflammation, epigenetics, cardiac function, oxidative stress, extracellular matrix. The determination of biomarkers that are of diagnostic value for predicting the severity, progression of PH and response to therapy, in a simple blood test or condensate of exhaled air, can significantly reduce treatment costs and improve PH management.